CDC14B

Across TCGA pan-cancer cohorts, CDC14B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDC14B data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDC14B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CDC14B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where CDC14B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.889	1.000	.011	30	view →
UCEC	OS	Quartile	II,III,IV	0.508	1.000	.035	8	view →
LUAD	OS	Median	II,III,IV	0.893	0.449	.024	4	view →
HNSC	OS	Quartile	IV	0.632	0.904	.028	1	view →
GBM	DFS	Median	All	0.877	0.643	.016	1	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.874	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDC14B–CCRCC (OS)

Open the CCRCC breakdown →